HEILBRONN, Germany, March 29, 2016 — XENIOS announced today that the first patient has been enrolled in the “SynCor” clinical trial of its i-cor Synchronized Cardiac Assist System for treating cardiogenic shock. The SynCor trial is a prospective, non-randomized, multi-center, open-label observational study of the safety and performance of the i-cor ...

Partnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENIOS expected in 2017.

45th annual meeting of the DGTHG & 48th annual meeting of the DGPK, Leipzig

We want to thank all visitors for participating in our priming challenge and for visiting our lunch symposium “Pediatric lung & heart assist reaching the next level”.